Discovery and evaluation of inhibitory activity and mechanism of arylcoumarin derivatives on Theileria annulata enolase by in vitro and molecular docking studies
Özet
Abstract: In this study, the inhibition potential of 3- and 4-arylcoumarin derivatives on Theileria annulata enolase (TaENO) was assessed for the first time in the literature. Firstly, protein stabilization analyses of TaENO were performed and it was found that the enzyme remains stable with the addition of 6 M ethylene glycol at + 4 °C. Inhibitor screening analyses were carried out using 25 coumarin derivatives on highly purified TaENO (> 95%), and four coumarin derivatives [4-(3,4-dimethoxyphenyl)-6,7-dihydroxy-2H-chromen-2-one (C8); 4-(3,4-dihydroxyphenyl)-7,8 dihydroxy-2H-chromen-2-one (C9); 4-(3,4-dihydroxyphenyl)-6,7-dihydroxy-2H-chromen-2 one (C21); and 3-(3,4-dihydroxyphenyl)-7,8-dihydroxy-2H-chromen-2-one (C23)] showed the highest inhibitory effects with the IC50 values of 10.450, 13.170, 8.871 and 10.863 µM, respectively. The kinetic results indicated that these compounds inhibited the enzyme by uncompetitive inhibition. In addition, the successful binding of the most potent inhibitor (C21) into TaENO was confirmed by using MALDI-TOF mass spectrophotometry. Molecular docking analyses have predicted that C8 and C21 coumarin derivatives which showed high inhibitory effects on TaENO were interacted with high affinity to the potential regions out of the active site. Taken together, these coumarin derivatives (C8, C9, C21 and C23) are first known potent, nonsubstrate, uncompetitive inhibitors of TaENO and these results will facilitate further in vitro and in vivo analysis toward structure-based drug design studies. Graphic abstract: [Figure not available: see fulltext.]
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Yakarsonmez, Sinem | |
| dc.contributor.author | Danis, Ozkan | |
| dc.contributor.author | Mutlu, Ozal | |
| dc.contributor.author | Topuzogullari, Murat | |
| dc.contributor.author | Sariyer, Emrah | |
| dc.contributor.author | Yuce-Dursun, Basak | |
| dc.contributor.author | Turgut-Balik, Dilek | |
| dc.date.accessioned | 2026-10-22T10:20:36.486020315Z | |
| dc.date.available | 2026-10-22T10:20:36.486020315Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Abstract: In this study, the inhibition potential of 3- and 4-arylcoumarin derivatives on Theileria annulata enolase (TaENO) was assessed for the first time in the literature. Firstly, protein stabilization analyses of TaENO were performed and it was found that the enzyme remains stable with the addition of 6 M ethylene glycol at + 4 °C. Inhibitor screening analyses were carried out using 25 coumarin derivatives on highly purified TaENO (> 95%), and four coumarin derivatives [4-(3,4-dimethoxyphenyl)-6,7-dihydroxy-2H-chromen-2-one (C8); 4-(3,4-dihydroxyphenyl)-7,8 dihydroxy-2H-chromen-2-one (C9); 4-(3,4-dihydroxyphenyl)-6,7-dihydroxy-2H-chromen-2 one (C21); and 3-(3,4-dihydroxyphenyl)-7,8-dihydroxy-2H-chromen-2-one (C23)] showed the highest inhibitory effects with the IC50 values of 10.450, 13.170, 8.871 and 10.863 µM, respectively. The kinetic results indicated that these compounds inhibited the enzyme by uncompetitive inhibition. In addition, the successful binding of the most potent inhibitor (C21) into TaENO was confirmed by using MALDI-TOF mass spectrophotometry. Molecular docking analyses have predicted that C8 and C21 coumarin derivatives which showed high inhibitory effects on TaENO were interacted with high affinity to the potential regions out of the active site. Taken together, these coumarin derivatives (C8, C9, C21 and C23) are first known potent, nonsubstrate, uncompetitive inhibitors of TaENO and these results will facilitate further in vitro and in vivo analysis toward structure-based drug design studies. Graphic abstract: [Figure not available: see fulltext.] | |
| dc.description.sponsorship | General Directorate of Agricultural Research and Policies of Republic of Turkey Ministry of Food, Agriculture and Livestock, (TAGEM-14/AR-GE/17) | |
| dc.description.sponsorship | TUBITAK, (BIDEB) | |
| dc.identifier.doi | 10.1007/s11030-019-10018-9 | |
| dc.identifier.eissn | 1573-501X | |
| dc.identifier.endpage | 1164 | |
| dc.identifier.issn | 1381-1991 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pmid | 31754915 | |
| dc.identifier.scopus | 2-s2.0-85075365125 | |
| dc.identifier.startpage | 1149 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/gumushane/12840 | |
| dc.identifier.volume | 24 | |
| dc.identifier.wos | WOS:000498621700001 | |
| dc.language.iso | en | |
| dc.publisher | Springer Science and Business Media Deutschland GmbH | |
| dc.relation.ispartof | Molecular Diversity | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Coumarin | |
| dc.subject | Drug resistance | |
| dc.subject | Enolase | |
| dc.subject | Enzyme inhibition | |
| dc.subject | Structure-based drug design | |
| dc.subject | Theileriosis | |
| dc.subject.classification | Biochemistry & Molecular Biology | |
| dc.subject.classification | Chemistry, Applied | |
| dc.subject.classification | Chemistry, Medicinal | |
| dc.subject.classification | Chemistry, Multidisciplinary | |
| dc.subject.classification | Chemistry | |
| dc.subject.classification | Pharmacology & Pharmacy | |
| dc.subject.other | Catalytic Domain | |
| dc.subject.other | Coumarins | |
| dc.subject.other | Drug Design | |
| dc.subject.other | Kinetics | |
| dc.subject.other | Molecular Docking Simulation | |
| dc.subject.other | Phosphopyruvate Hydratase | |
| dc.subject.other | Structure-Activity Relationship | |
| dc.subject.other | Theileria annulata | |
| dc.subject.other | 3 (3,4 dihydroxyphenyl) 7,8 dihydroxy 2h chromen 2 one | |
| dc.subject.other | 4 (3,4 dihydroxyphenyl) 6,7 dihydroxy 2h chromen 2 one | |
| dc.subject.other | 4 (3,4 dihydroxyphenyl) 7,8 dihydroxy 2h chromen 2 one | |
| dc.subject.other | 4 (3,4 dimethoxyphenyl) 6,7 dihydroxy 2h chromen 2 one | |
| dc.subject.other | coumarin derivative | |
| dc.subject.other | enolase | |
| dc.subject.other | ethylene glycol | |
| dc.subject.other | lyase inhibitor | |
| dc.subject.other | unclassified drug | |
| dc.subject.other | 2H-chromen-2-one | |
| dc.subject.other | coumarin | |
| dc.subject.other | Article | |
| dc.subject.other | binding affinity | |
| dc.subject.other | controlled study | |
| dc.subject.other | drug potency | |
| dc.subject.other | drug research | |
| dc.subject.other | drug screening | |
| dc.subject.other | drug structure | |
| dc.subject.other | enzyme active site | |
| dc.subject.other | enzyme analysis | |
| dc.subject.other | enzyme inhibition | |
| dc.subject.other | enzyme inhibitor interaction | |
| dc.subject.other | enzyme purification | |
| dc.subject.other | enzyme stability | |
| dc.subject.other | IC50 | |
| dc.subject.other | in vitro study | |
| dc.subject.other | inhibition kinetics | |
| dc.subject.other | matrix assisted laser desorption ionization time of flight mass spectrometry | |
| dc.subject.other | molecular docking | |
| dc.subject.other | nonhuman | |
| dc.subject.other | priority journal | |
| dc.subject.other | uncompetitive inhibition | |
| dc.subject.other | chemistry | |
| dc.subject.other | drug effect | |
| dc.subject.other | procedures | |
| dc.subject.other | structure activity relation | |
| dc.title | Discovery and evaluation of inhibitory activity and mechanism of arylcoumarin derivatives on Theileria annulata enolase by in vitro and molecular docking studies | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.openalex | 6 | |
| rdl.citation.scopus | 5 | |
| rdl.citation.wos | 5 | |
| rdl.department | Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Gumushane University, 29100, Gumushane, Turkey | |
| rdl.oa.status | closed | |
| rdl.sdg | SDG03 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |

